These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12145543)

  • 1. Accurate prediction of response to interferon therapy by repeated measurement of hepatitis C virus core protein in patients with chronic hepatitis C.
    Nishiguchi S; Enomoto M; Tanaka M; Fukuda K; Tamori A; Habu D; Takeda T; Shiomi S; Tanaka T; Yano Y; Otani S
    Intervirology; 2002; 45(2):105-10. PubMed ID: 12145543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon.
    Shiratori Y; Kato N; Yokosuka O; Hashimoto E; Hayashi N; Nakamura A; Asada M; Kuroda H; Ohkubo H; Arakawa Y; Iwama A; Omata M
    J Hepatol; 1997 Sep; 27(3):437-44. PubMed ID: 9314119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads.
    Enomoto M; Nishiguchi S; Tamori A; Kohmoto M; Habu D; Sakaguchi H; Takeda T; Kawada N; Seki S; Shiomi S
    J Med Virol; 2005 Sep; 77(1):77-82. PubMed ID: 16032731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
    Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
    Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.
    Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; Elhefnawi M; Zaid A; Al-Qahtani AA
    J Med Virol; 2014 Feb; 86(2):224-34. PubMed ID: 24166351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
    J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.
    Buti M; Mendez C; Schaper M; Sauleda S; Valdes A; Rodriguez-Frias F; Jardi R; Esteban R
    J Hepatol; 2004 Mar; 40(3):527-32. PubMed ID: 15123370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HCV genotype as a predictor of response to interferon therapy in patients with chronic hepatitis C].
    Orito E
    Nihon Rinsho; 2001 Jul; 59(7):1356-62. PubMed ID: 11494551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
    Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa.
    Tanaka E; Kiyosawa K; Matsumoto A; Kashiwakuma T; Hasegawa A; Mori H; Yanagihara O; Ohta Y
    Hepatology; 1996 Jun; 23(6):1330-3. PubMed ID: 8675147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The factors associated with viral relapse after interferon treatment in chronic hepatitis C patients].
    Ma L; Zhao H; Xie Y; Li MH; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Aug; 14(8):565-8. PubMed ID: 16938164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between histological prognosis of chronic hepatitis C and amount of hepatitis C virus core protein in serum.
    Iijima A; Tanaka E; Kobayashi M; Yagi S; Mizokami M; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Mar; 15(3):311-9. PubMed ID: 10764034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
    Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.
    Fujino T; Nakamuta M; Aoyagi Y; Fukuizumi K; Takemoto R; Yoshimoto T; Miyahara T; Harada N; Sakai H; Nakashima M; Enjoji M
    J Dig Dis; 2009 Feb; 10(1):21-5. PubMed ID: 19236543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
    Higashimoto M; Takahashi M; Jokyu R; Saito H
    Rinsho Byori; 2006 Feb; 54(2):111-5. PubMed ID: 16548229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.